Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease. It is characterized by a Bcr-Abl (breakpoint cluster region-Abelson leukemia virus) tyrosine kinase fusion protein produced from the Philadelphia (Ph) chromosome. The tyrosine kinase inhibitor (TKI) imatinib was the first targeted therapy licensed for patients with chronic-phase CML. In recent years, many other TKIs have been approved for the treatment of patients with CML. For this reason, the choice of the best strategy treatment has become increasingly complex
Rusconi, F., Piazza, R., Vagge, E., GAMBACORTI PASSERINI, C. (2014). Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia. EXPERT OPINION ON PHARMACOTHERAPY, 15(5), 701-710 [10.1517/14656566.2014.882898].
Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia
RUSCONI, FRANCESCA;PIAZZA, ROCCO GIOVANNI;GAMBACORTI PASSERINI, CARLO
2014
Abstract
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease. It is characterized by a Bcr-Abl (breakpoint cluster region-Abelson leukemia virus) tyrosine kinase fusion protein produced from the Philadelphia (Ph) chromosome. The tyrosine kinase inhibitor (TKI) imatinib was the first targeted therapy licensed for patients with chronic-phase CML. In recent years, many other TKIs have been approved for the treatment of patients with CML. For this reason, the choice of the best strategy treatment has become increasingly complex
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
